Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MST1R Antibodies:
anti-Mouse (Murine) MST1R Antibodies:
anti-Rat (Rattus) MST1R Antibodies:
Go to our pre-filtered search.
Human Monoclonal MST1R Primary Antibody for ELISA, WB - ABIN969384
Lee, Chen, Chow, Su, Lin, Guo: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. in Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Show all 3 Pubmed References
Human Polyclonal MST1R Primary Antibody for FACS - ABIN4896927
Sie, den Dunnen, Lourens, Meeuwsen-de Boer, Scherpen, Zomerman, Kampen, Hoving, de Bont: Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. in PLoS ONE 2015
Human Polyclonal MST1R Primary Antibody for IHC (p) - ABIN2478412
Wang, Zhou, Chen: Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities. in Scandinavian journal of immunology 2002
Human Polyclonal MST1R Primary Antibody for WB - ABIN392048
Penengo, Rubin, Yarden, Gaudino: c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. in Oncogene 2003
Show all 4 Pubmed References
Findings indicate a role of the RON tyrosine kinase receptor (show NTRK1 Antibodies) in pancreatic cancer and suggest RON as a potential therapeutic target.
High expression of RON is associated with drug resistance in bladder cancer.
complete loss of one or both MET and RON, as well as their overexpression, is a poor prognostic factor in patients with extrahepatic cholangiocarcinoma, probably due to the high rate of lymph-node metastasis
Study identified four novel uniquely spliced RON transcripts in small cell lung carcinoma (SCLC) and Non-SCLC cell lines.
the MST1R variant c.G917A:p.R306H is highly associated with nasopharyngeal carcinoma (odds ratio of 9.0).
Results show that under hypoxia, nuclear RON activates non-homologous end joining DNA repair by interacting with Ku70 (show XRCC6 Antibodies) and DNA-PKcs (show PRKDC Antibodies) and confers chemoresistance.
Aberrant glycosylation of the RON receptor was shown as an alternative mechanism of oncogenic activation.
Data demonstrated upregulated RON isoform expression and significant changes in splicing factor (show SLU7 Antibodies) expression in primary ovarian cancer suggesting a regulatory interplay of splicing factor (show SLU7 Antibodies) and RON alternative splicing pattern in ovarian cancer.
Activation of RON as an alternate mechanism in the development of CRPC.
the prognostic significance of MET is limited in early stage disease. MET+/RON+ patients had higher overall recurrence rates than those with the other expression patterns
this study shows that Ron is expressed in a subpopulation of macrophages during chronic inflammation induced by obesity that exhibit a repair phenotype as determined by the expression of arginase 1 (show ARG1 Antibodies)
Report Ron receptor-dependent gene regulation of inflammatory/anti-inflammatory gene expression in Kupffer cells during endotoxemia.
Ron knockdown further sensitized breast cancer cells to the growth inhibitory effects of vitamin D3, while constitutive activation of beta-catenin (show CTNNB1 Antibodies) reverted the effects of vitamin D3.
Studies demonstrate that DEK (show DEK Antibodies) overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling.
A previously unknown function for the Ron receptor in mediating High Fat Diet-induced obesity and metabolic dysregulation.
important functional roles for Ron in inflammatory bowel diseases by regulating healing of the colonic epithelium and by controlling cytokine secretion
DC-STAMP (show TM7SF4 Antibodies), Siglec-15 (show SIGLEC15 Antibodies), Tspan7 (show TSPAN7 Antibodies) and Mst1r expression was downregulated by docosahexaenoic acid, but not eicosapentaenoic acid during osteoclastogenesis in vitro.
Stem cell-derived tyrosine kinase plays a role in regulating macrophage recruitment and activation in the liver following acetaminophen administration and in hepatotoxicity.
studies show a critical role for the Ron receptor in the tumor microenvironment, whereby Ron loss in tumor-associated macrophages inhibits prostate cancer cell growth, at least in part, by derepressing the activity of CD8 (show CD8A Antibodies)(+) T cells
Identify a novel signaling mechanism by which the Ron receptor regulates acute liver failure progression.
This gene encodes a cell surface receptor for macrophage-stimulating protein (MSP) with tyrosine kinase activity. The mature form of this protein is a heterodimer of disulfide-linked alpha and beta subunits, generated by proteolytic cleavage of a single-chain precursor. The beta subunit undergoes tyrosine phosphorylation upon stimulation by MSP. This protein is expressed on the ciliated epithelia of the mucociliary transport apparatus of the lung, and together with MSP, thought to be involved in host defense. Alternatively spliced transcript variants encoding different isoforms with different structural and biochemical properties have been described (PMID:8816464).
, MST1R variant RON30
, MST1R variant RON62
, PTK8 protein tyrosine kinase 8
, RON variant 21
, RON variant E2E3
, c-met-related tyrosine kinase
, macrophage-stimulating protein receptor
, soluble RON variant 1
, soluble RON variant 2
, soluble RON variant 3
, soluble RON variant 4
, friend virus susceptibility 2
, macrophage-stimulating protein receptor precursor (MSP receptor) (p185-Ron) (Stem cell-derived tyrosine kinase)
, receptor protein tyrosine kinase, c-met-related
, stem cell-derived tyrosine kinase
, protein tyrosine kinase 8
, tyrosine kinase receptor ron